Sterile injectable CDMOs in India are expanding their capabilities in fill-finish operations, advanced technologies, regulatory compliance, and the manufacturing of complex drugs.
AI drug discovery is gaining ground in India's pharmaceutical R&D landscape, with Rasayan Labs and ICT Mumbai bringing computational chemistry, molecular design and synthesis planning into a unified drug-discovery workflow.
InnoCare and Eli Lilly have signed drug discovery pacts worth up to 3.35 billion, strengthening global interest in Chinese innovation.
Claude AI uncovers a novel enzyme system with CRISPR-like features, marking Anthropic’s first public biology research result and expanding AI-driven biological discovery.
Today in Pharma highlights major deals and alliances, from Novartis’ radioligand therapy agreement with BoomRay to IMA and Abbott’s adult immunization drive.
India renews its global pledge on hepatitis elimination, reaffirming its commitment to end Hepatitis B through prevention, treatment, and equitable care.
AbbVie joins the AI drug-discovery race with Iambic, applying advanced molecular AI to accelerate small-molecule discovery across core therapeutic areas.
Ayurveda needs stronger research, scientific validation, and safety monitoring to build a credible pipeline from traditional knowledge to market-ready products.
Regulatory watch intensifies as the EU and FDA clear new treatments while India rewires sterile-drug licensing, digital regulation and CDSCO capacity.
This Week in Biosimilars highlights oncology taking the Lead in India as Dr. Reddy’s enters the nivolumab market and competition expands patient access.
.jpg)
, CDSCO.jpg)